Pavan Kumar Yadav Selected Research

asolectin

12/2022

Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pavan Kumar Yadav Research Topics

Disease

5	Neoplasms (Cancer) 01/2021 - 02/2016
2	Breast Neoplasms (Breast Cancer) 09/2021 - 03/2020
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2017
1	Hemolysis 12/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2022
1	Carcinogenesis 03/2020

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2017 - 02/2016
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2017
2	AntigensIBA 01/2021 - 03/2020
2	Extracellular Matrix ProteinsIBA 01/2021 - 03/2020
2	Neoplasm Antigens (Tumor Antigens)IBA 03/2020 - 09/2016
1	ErbB Receptors (EGF Receptor)IBA 12/2022
1	asolectinIBA 12/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2022
1	Pharmaceutical PreparationsIBA 12/2022
1	Ether (Diethyl Ether)IBA 12/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2022
1	SolutionsIBA 12/2022
1	MicellesIBA 09/2021
1	baicaleinIBA 09/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2021
1	VaccinesIBA 01/2021
1	Interleukin-18 (Interleukin 18)IBA 03/2020
1	DNA (Deoxyribonucleic Acid)IBA 03/2020
1	DNA VaccinesIBA 03/2020
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 03/2020
1	Tissue Inhibitor of Metalloproteinase-3IBA 01/2017
1	Poly I-CIBA 09/2016
1	LigandsIBA 09/2016
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 02/2016
1	Viral ProteinsIBA 02/2016

Therapy/Procedure

2	Immunotherapy 01/2021 - 03/2020